Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report for the Period April 1, 2020 to June 30, 2020

April – June 2020 in Summary · Total revenue amounted to SEK 162.6 million. Net revenue amounted to SEK 138.0 million which represents a growth of 1014% compared to the same period last year · EBITDA amounted to SEK 18.7 million · The cash balance amounted to SEK 144.7 million · Net debt was SEK 74.8 million · Equity amounted to SEK 306.1 million · Earnings per share amounted to SEK -0.12. April – June 2020 in Summary Pro-Forma* · Total revenue amounted to SEK 189.1 million. · EBITDA amounted to SEK 26.6 million. Rolling 12 Months in Summary Pro-Forma*

EG7 Enters Into an Agreement to Acquire Big Blue Bubble

EG7 Enters Into an Agreement to Acquire Big Blue Bubble INSIDE INFORMATION: Enad Global 7 AB (publ) ("EG7"), has today entered into an agreement with the owners of Canadian game developer Big Blue Bubble Inc. (“Big Blue Bubble”) to acquire 100 percent of Big Blue Bubble (the “Transaction”) for a consideration of CAD 16 million, plus an additional consideration of up to CAD 60 million, on a cash- and debt- free basis paid in cash and in newly issued EG7 shares (the “Consideration”). Big Blue Bubble is a gaming industry mainstay that has released more than 100 titles; its own IP as well as

Mandatory Notification of Trade – Options

Reference is made to the announcement on 5 April, 2017, in which Hexagon Composites ASA (the "Company") announced the grant of 1,640,000 share options to employees under its employee share option program, each at a strike price of NOK 27 per share. Of the 1,640,000 options, 1,175,000 options were granted to senior executives and managers listed as primary insiders. The options may be exercised in part or in full within three weeks following the official announcement of the financial results for the fourth quarter of 2019, first quarter of 2020 and second quarter of 2020. Pursuant to

EU and Sectra sign framework agreement for secure communications

Linköping, Sweden – August  27, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed a new framework agreement for the approved mobile encryption system, Sectra Tiger, with the European External Action Service, the Council of the European Union and the European Commission. This framework agreement will help EU organizations to communicate securely and efficiently among themselves and with EU member states, without risking the confidentiality of their information.“It is vital for us to be able to communicate securely. The

2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.

The half-year report is available as an attached document as well as on the company’s website (www.2curex.com). Below follows a short summary of the report.CEO Ole Thastrup comments “2cureX pushes forward on its clinical trials within colorectal, ovarian and pancreatic cancer. Despite delays due to the COVID-19 pandemic, 2cureX still plans to launch IndiTreat® in 2020. To support our market strategy, we have established our first clinical partnership with a major Swedish hospital (Skåne University Hospital) besides entering into a distributor agreement for Portugal and Spain. The Early

Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study

Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized cancer. The data presented today displays an encouraging safety profile of ATOR-1017. Few drug related adverse events have been observed and all were mild or moderate (grade 1 or 2). The Data Review Committee that monitors the safety of the patients in the ATOR-1017 Phase I study, has cleared the 40 mg dose and approved to

TagMaster receives award for mobile app GiveMeGreen! and new order in US

Press release, Stockholm, Sweden August 27, 2020  TagMaster, the leading supplier of advanced sensor systems for Smart Cities within Traffic and Rail, has through its American subsidiary Sensys Networks been awarded the ITE Transportation Achievement Award for the development and installation of GiveMeGreen! - a mobile app that makes it possible to detect bicyclists as they approach an intersection. Sensys Networks receives the award together with the city of Santa Clara, California, where GiveMeGreen! was first implemented. Sensys Networks has also received an order from the city of

Half year report Scandinavian Enviro Systems AB (publ) January – June 2020

The partnership with Michelin confirms Enviro's technology and commercial potential.N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Q2 2020 · Net revenues for the period were MSEK 0.2 (0.1) · Earnings after tax for the period were MSEK -11.9 (-11.4) · Earnings per share for the period (before dilution) was SEK -0.02 (-0.03) · Cash flow for the period after investments was MSEK -11.4 (-11.4) · The company has completed a directed share

Interim Report January–June 2020

ChromoGenics adopts a position for accelerated growthQ2 2020 · Net sales for the period amounted to SEK 4.0 (12.5) million, and earnings amounted to SEK -18.9 (-18.3) million, which corresponds to earnings per share of SEK - 0.03 (-0.11). · ChromoGenics continued to be affected by the coronavirus pandemic during the second quarter, which resulted in delayed orders from the company’s customers. Order intake and invoicing have been postponed in 2020. Net sales in the current year are therefore expected to be lower than net sales in 2019. An action program to reduce the company’s

Endomines AB Half-year interim report 2020 – First shipments of gold concentrate from the Friday mine

Endomines AB, Stock Exchange Release 27 August 2020 at 08:30 CET H1 2020 (vs. H1 2019) Operational highlights · Endomines announces first shipments of gold concentrate from the Friday mine · Endomines announces agreement with Transatlantic Mining to buy US Grant mine and mill and Kearsarge Gold Project · No injuries reported in the last 12 months; LTIFR 0 (11) Financial highlights · Total revenue was 10.5 MSEK (3.5) · EBITDA was -45.3 MSEK (-20.8) · Total cash flow was -12.3 MSEK (-13.2) · Earnings per share was -0.61 SEK (-0.57) Outlook:The COVID-19

DOF Subsea awarded multiple contracts by Petrobras

DOF Subsea is proud to announce four new contracts with Petrobras. The contracts include work within our core service lines for Survey and Inspection. At least three vessels from the DOF fleet shall be mobilised to perform flexible pipeline, risers and subsea equipment inspection in Campos Basin, Santos Basin, Marlin Field and Espírito Santos Basin. The contracts are worth more than USD 110 million with planned commencement in Q4 2020 and estimated to be performed within 550 days. Mons S Aase, CEO, DOF Subsea said, “I am very pleased for these awards securing utilisation for our

Optomed ’s financial reporting in 2021

Optomed Plc         Stock Exchange Release    27 August 2020 at 9.15, Helsinki Optomed’s financial reporting in 2021 Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2021 as follows: · Financial Statement Bulletin for 1 January – 31 December 2020, 18 February 2021 · Interim Report for 1 January – 31 March 2021, 6 May 2021 · Half-Year Financial Report for 1 January – 30 June 2021, 5 August 2021 · Interim Report for 1 January – 30 September 2021, 4 November 2021 Annual Report 2020, which includes the company’s

PHI granted patent on synthetic antibodies in the U.S.

Phase Holographic Imaging AB (PHI) announces today that the Company has been granted a patent (US10730986B2 ) on synthetic antibodies from the United States Patent and Trademark Office (USPTO). PHI submitted the patent application "Molecularly Imprinted Polymers" together with Germany’s federal institute for materials research (BAM) to the USPTO on November 20, 2017."The approval of the patent in the U.S. marks a significant milestone for the

American Shipping Company ASA - Ex-dividend today

Lysaker, 27 August 2020, Ex-dividend today Reference is made to the Company's Q2 2020 report, regarding the Board's authorization to pay a quarterly dividend of USD 0.10 per share to the shareholders of AMSC on record as of 28 August 2020.  The shares in American Shipping Company ASA will be traded ex dividend USD 0.10 as from today, 27 August 2020.  The NOK amount per share will be 0.8958 and will be paid on or about 7 Septmeber 2020.  The dividend is classified as a return of paid in capital. *** About American Shipping Company ASA: Established in 2005 and listed on the OSE,

Flexion Mobile launches Tabou Stories in its key channels

LONDON, 27th of August, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has launched Tabou Stories: Love Episodes from Nanobit. Nanobit is one of the leading developers of Interactive story based games, a genre that has become very popular. Tabou Stories was launched in Google Play in February and has rapidly grown its user base and revenues. This is the 3rd title that Flexion distributes from Nanobit. The game is now live in Flexion's core channels, Samsung, Huawei and Amazon. "In just two weeks we have launched 3 new games and I

Half year interim report Frill Holding AB

STOCKHOLM, Thu, August 27, 2020 08.00 CETFrill Holding AB publishes half year interim report January to June 2020. Financial overview · Net sales for the period amounted to 1 173 TSEK (1 144) · EBIT for the period amounted to –5 837 TSEK (-8 673) · Equity at the end of the period amounted to 37 257 TSEK (24 943) · Earnings per share totalled SEK -0.2 (-0.4) · Cash flow from operating activities amounted to -4 936 TSEK (-7 615) · Cash and cash equivalents at the end of the period amounted to 862 TSEK (4 108) · In July 2020, the company received 15 155 TSEK (before

Tradedoubler Interim Report January - June 2020

The second quarter April - June 2020 · Net sales amounted to SEK 287 M (289) a decrease of -1% or 0% adjusted for changes in exchange rates compared to the same period last year. · Gross profit was SEK 64 M (65), a decrease of -1% and -1% adjusted for changes in exchange rates. Gross margin was 22.4% (22.5). · Operating costs excluding depreciation and change related items were SEK 50M (56), a decrease of -11%. · EBITDA amounted to SEK 14 M (7). Adjusted for change related items, EBITDA was SEK 14 M (9). · Capitalised expenses for product development were SEK 6 M (5). ·

Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months

Data on exploratory efficacy endpoints continue to show a promising biological signal in some patientsHerantis Pharma PlcCompany release August 27, 2020 at 9:00 AM Eastern European Summer Time Herantis Pharma Plc (“Herantis” or “Company”) announced today that its novel drug candidate, Cerebral Dopamine Neurotrophic Factor (CDNF) for the treatment of Parkinson’s disease (PD), has successfully achieved its primary endpoint of safety and tolerability in a 12 month Phase I-II study in patients with moderate disease. CDNF is a multi- modal, natural protein that has shown potential to slow

Skanska divests multifamily housing portfolio in Skåne, Sweden, to KPA Pension for about SEK 1.5 billion

Skanska has sold a portfolio of five multifamily projects in Skåne, Sweden, for a total of approximately SEK 1.5 billion. The investor is KPA Pension. The transaction will be recognized by Skanska Sweden in the business stream residential development in the third quarter of 2020.The transaction relates to projects in Malmö, Lund, Helsingborg and Ängelholm that are being developed and constructed by Skanska Sweden. The portfolio includes a range of products, from townhouse-style condominiums to buildings eight stories tall totaling approximately 600 apartments. All projects are being

Polygiene AB (publ.) Interim Report 1 April–30 June 2020

ViralOff[®] success, record number of new agreementsQ2 in brief · Positive growth due to increased net sales by 37.4 % during the quarter compared to the same period last year and amounted to MSEK 17.3 (12.6). · The operating profit/loss before tax for the period has improved compared to the same period last year and amounted to MSEK -1.1 (-5.4). · The gross margin has decreased at 70.3 (72.1) %. · Cash flow remained unchanged of the second quarter, MSEK 0.0 (-2.2). Events during Q2 2020 (Aril-June) · In connection with the launch of ViralOff the company strengthens

Clavister Q2 2020: All-time High Order Intake and Positive Operating Cash-flow

August 27, 2020, Örnsköldsvik, Sweden. Clavister, a leader in high-performance cybersecurity solutions, released its second quarterly 2020 interim report today.  “Our second quarter of 2020 saw record order intake, important customer contract wins as well as some operational impacts of the Covid-19 pandemic. Positive operating cash-flow in the period was mainly attributed to improved invoiced sales, higher gross margins and cost and cash management. Our order intake for the second quarter increased by 49% (adjusted for China) and ended at an all-time high level of 55 MSEK. The

IRRAS AB publishes Interim Report for the period January to June 2020

Market begins to brighten after lockdowns “In the second quarter, IRRAS made several advances in the ongoing commercialization of IRRAflow and Hummingbird, despite the fact that the extensive covid-19 restrictions were a highly disruptive and delaying factor. The covid-19 pandemic continues to limit our commercial activities and access to hospitals in countries around the world. However, compared with the widespread lockdowns in the second quarter, the situation is starting to improve. At the beginning of the third quarter, for the first time since the lockdowns came into force, we

Notice of Half-Year Report

Faron Pharmaceuticals Ltd (“Faron” or the “Company”)Company announcement, 27 August 2020 at 9.00 AM (EET) TURKU – FINLAND, 27 August 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, will announce its unaudited half-year report for the six months ended 30 June 2020 on Thursday 24 September 2020. Dr. Markku Jalkanen, Chief Executive Officer, Toni Hänninen, Chief Financial Officer, and Yrjö Wichmann, VP Financing will host a conference call and webcast followed by a Q&A session at 12:30 pm BST (7:30 am EST) to discuss the financial

There are no items matching the current filter
There are no more items matching the current filter
Back to top